What Clinicians Want to Know About Toxicity Considerations Associated with BTK Inhibitors

Summary: Dr Nicole Lamanna from the Columbia University Herbert Irving Comprehensive Cancer Center in New York, New York, and Dr William G Wierda from The University of Texas MD Anderson Cancer Center in Houston, Texas, discuss the spectrum of toxicities associated with BTK inhibitors and strategies for their mitigation and management for patients with chronic lymphocytic leukemia and mantle cell lymphoma.